This week the Cancer Conference Coverage moves to the joint IASLC-AACR symposium on the Molecular Origins of Lung Cancer in San Diego.  Having attended previous events (this is the third one they’ve hosted) and rather enjoyed them, this year I’m following it remotely.

What’s particularly nice about this type of specialist event is that they are especially useful for chatting informally with attendees and being able to ask a lot of questions that simply wouldn’t be feasible at larger meetings due to time and other constraints.

This review covers my thoughts on two immunotherapies, namely Merck’s anti-PD-1, which was previously presented at the World Lung Conference, plus a completely novel and very different approach that looks really quite exciting.

You can sign in or sign up below to read more tangible details.

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR, COMMUNICATIONS OR MEDIA (that includes JOURNALISTS & WRITERS), you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you are in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first. Please note that we do not collect or remit any sales taxes. The purchaser is solely responsible for ensuring compliance with tax laws where they reside or use our content and for the reporting and payment, at their expense, of any use tax or other taxes that may be due as a result of this purchase. An accountant, tax advisor or lawyer should be consulted for advice on any obligation.